DocDollars

Agios Pharmaceuticals, Inc.

MA · United States · Reporting entity ID 100000181751

Total reported 2019–2025
$58.3M
#151 of 2,960 reporting companies — 0.1% of all reported industry payments
$10.6M in general payments across 15,712 records, plus $47.8M in research funding across 5,629 records.

How it breaks down

General payments $10,581,895
Research funding $47,755,236

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Agios Pharmaceuticals, Inc. reported $58.3M to US doctors and teaching hospitals from 2019 to 2025, ranking #151 of 2,960 reporting companies. 82% of that was research funding and 18% general payments such as consulting, speaking, food and travel. 15,712 general payment records and 5,629 research records were filed.

Common questions about Agios Pharmaceuticals, Inc.

How much has Agios Pharmaceuticals, Inc. paid US doctors?

Agios Pharmaceuticals, Inc. reported $58,337,131 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $10,581,895 in general payments, $47,755,236 in research funding.

How does Agios Pharmaceuticals, Inc. rank among drug and device companies?

It ranks #151 of 2,960 reporting entities by total reported value, about 0.1% of all industry payments in the dataset.

Does a payment from Agios Pharmaceuticals, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.